Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified post-transplant cyclophosphamide plus mycophenolate mofetil to induce immune tolerance after allogeneic peripheral blood stem cell transplantation
ChiCTR2200064513Phase 3Recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jul 2022
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cyclophosphamide, mycophenolate mofetil and tacrolimus, sponsored by Xiangya Hospital, Central South University. Primary endpoints: Engraftment incidence and Incidence and extent of graft-versus-host disease. Started Jul 2022; status: recruiting.
02
Drugs
cyclophosphamidemycophenolate mofetiltacrolimus
Beyond the preview
Go deeper on ChiCTR2200064513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064513.